Navigation Links
Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Company's Latest Announcement
Date:5/19/2009

WOODMERE, N.Y., May 19 /PRNewswire/ -- The Quigley Corporation (Nasdaq: QGLY) announced yesterday that its Board was exploring various options, including hiring an investment banker and exploring "strategic alternatives".

Ted Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark Leventhal, and James McCubbin ("the Shareholder Nominees") believe that the recent announcement is an 11th hour attempt to obtain shareholder votes and is further evidence of the need for a slate of new highly qualified directors to protect the interests of all shareholders.

"Shareholders should ask why the incumbents released this announcement just two days before the shareholder meeting," commented Mr. Karkus. "A responsible Board should always be reviewing the Company's strategic alternatives," he added.

Ask yourself if you want the same Board that managed the Darius/Innerlight sale last year to execute any further "strategic alternatives". The Darius/Innerlight division was sold for a mere $1 million just before it turned around in early 2008. Please read our last press release which summarizes some of the many facts that trouble us with that transaction.

And, finally, ask yourself why they didn't pursue these "strategic alternatives" when the Company's OTC division had increasing sales and increasing profits, instead of now, when the division is likely to be worth significantly less, given declining sales, increasing losses and a weaker environment for selling assets.

For more information on the actions by Quigley management that have necessitated this proxy contest and the Federal Court's decision to reject Quigley's claims against the Shareholder Nominees, shareholders should refer to our previous press releases and the court order which are available at www.shareholdermaterial.com/QGLY

VOTING INSTRUCTIONS:

Only your last vote counts. Simply find the control # on our light blue shaded Voting Instruction Form. This is the voting form that has the Ted Karkus list of Shareholder Nominees on it. Then call (800) 454-8683 or go to www.proxyvote.com and input your control # when prompted. It is that simple to vote or to change your vote.

For any questions or assistance regarding the voting instructions, please call the Shareholder Nominees' proxy solicitor, The Altman Group, toll free at (866) 796-7175.

Mr. Karkus welcomes all calls to discuss the Company and its future with all shareholders. He is available at (516) 569-9999.

Important Additional Information

Ted Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark Leventhal and James McCubbin (the "Shareholder Nominees") filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on May 1, 2009 in connection with the 2009 Annual Meeting of Stockholders of The Quigley Corporation. Stockholders are strongly advised to read the Shareholder Nominees' proxy statement as it contains important information. Stockholders may obtain an additional copy of the Shareholder Nominee's definitive proxy statement and any other documents filed by them with the SEC for free at the SEC's website at http://www.sec.gov Additionally, copies of the definitive proxy statement are available for free at www.shareholdermaterial.com/qgly


'/>"/>
SOURCE Ted Karkus
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
2. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
3. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
4. Lab Series(R) Skincare For Men Spa Indulges the 2007 Primetime Emmy(R) Nominees at the Sofitel(R) Los Angeles
5. Erie Indemnity Announces Nominees for Board of Directors
6. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
7. Tennenbaum Encourages Shareholders to Vote the Blue Proxy for Tennenbaum Director Nominees at Online Resources Annual Meeting as Recommended by Riskmetrics/ISS and Proxy Governance
8. MMI Investments Issues Letter to Chemed Stockholders Illustrating the Superior Qualifications of the MMI Nominees
9. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
10. Americans United for Life Announces Legal Prospectus on Probable Supreme Court Nominees
11. Support Bristols Highly Qualified Independent Nominees for Advocat Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... set up in 2006 as a non-profit organization to unite pharmaceutical and healthcare ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. ... advocates for the mass media launching of story movements to highlight what's most ... their unfortunate experiences; such a movement can generate the network power to improve ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated ... it is one of the early adopters completing EU-U.S. Privacy Shield Certification from the ... provide companies on both sides of the Atlantic with a mechanism to comply with ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is ... by smoothing and tightening the skin of the face to create more youthful ... aging with very little downtime, Silhouette Instalift is a novel, minimally invasive facial ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- A Small Business Innovative Research (SBIR) grant has ... to Phoenix -based NeuroEM Therapeutics, Inc. ... will seek to determine an optimal set of treatment ... to treat Alzheimer,s Disease. The grant will also investigate ... other neurologic disorders such as Parkinson,s Disease and PTSD. ...
(Date:12/8/2016)... in the United States will continue in 2017, say ... December 2016 Semiannual Economic Forecast. Expectations are for a ... as indicated in the monthly ISM ® ... is optimistic about growth in 2017, with revenues expected ... sector indicates that 14 of its industries will see ...
(Date:12/8/2016)...  Hanson Research, an innovative leader in the ... testing instruments for the pharmaceutical industry, announced today ... ("Teledyne"). The move is designed to deepen investments ... as well as expand resources for further market ... services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
Breaking Medicine Technology: